Literature DB >> 23744781

A secreted PTEN phosphatase that enters cells to alter signaling and survival.

Benjamin D Hopkins1, Barry Fine, Nicole Steinbach, Meaghan Dendy, Zachary Rapp, Jacquelyn Shaw, Kyrie Pappas, Jennifer S Yu, Cindy Hodakoski, Sarah Mense, Joshua Klein, Sarah Pegno, Maria-Luisa Sulis, Hannah Goldstein, Benjamin Amendolara, Liang Lei, Matthew Maurer, Jeffrey Bruce, Peter Canoll, Hanina Hibshoosh, Ramon Parsons.   

Abstract

Phosphatase and tensin homolog on chromosome ten (PTEN) is a tumor suppressor and an antagonist of the phosphoinositide-3 kinase (PI3K) pathway. We identified a 576-amino acid translational variant of PTEN, termed PTEN-Long, that arises from an alternative translation start site 519 base pairs upstream of the ATG initiation sequence, adding 173 N-terminal amino acids to the normal PTEN open reading frame. PTEN-Long is a membrane-permeable lipid phosphatase that is secreted from cells and can enter other cells. As an exogenous agent, PTEN-Long antagonized PI3K signaling and induced tumor cell death in vitro and in vivo. By providing a means to restore a functional tumor-suppressor protein to tumor cells, PTEN-Long may have therapeutic uses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23744781      PMCID: PMC3935617          DOI: 10.1126/science.1234907

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  27 in total

Review 1.  The phosphoinositide 3-kinase pathway.

Authors:  Lewis C Cantley
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

2.  Context effects and inefficient initiation at non-AUG codons in eucaryotic cell-free translation systems.

Authors:  M Kozak
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

3.  Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors.

Authors:  Carlos Lois; Elizabeth J Hong; Shirley Pease; Eric J Brown; David Baltimore
Journal:  Science       Date:  2002-01-10       Impact factor: 47.728

4.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

5.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

6.  Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids.

Authors:  George McConnachie; Ian Pass; Steven M Walker; C Peter Downes
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

Review 7.  PTEN function: how normal cells control it and tumour cells lose it.

Authors:  Nick R Leslie; C Peter Downes
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

8.  Heterologous basic domain substitutions in the HIV-1 Tat protein reveal an arginine-rich motif required for transactivation.

Authors:  T Subramanian; R Govindarajan; G Chinnadurai
Journal:  EMBO J       Date:  1991-08       Impact factor: 11.598

9.  Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype.

Authors:  Liang Lei; Adam M Sonabend; Paolo Guarnieri; Craig Soderquist; Thomas Ludwig; Steven Rosenfeld; Jeffrey N Bruce; Peter Canoll
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

Review 10.  Brefeldin A: insights into the control of membrane traffic and organelle structure.

Authors:  R D Klausner; J G Donaldson; J Lippincott-Schwartz
Journal:  J Cell Biol       Date:  1992-03       Impact factor: 10.539

View more
  133 in total

Review 1.  Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy.

Authors:  Benjamin D Hopkins; Ramon E Parsons
Journal:  Clin Cancer Res       Date:  2014-11-01       Impact factor: 12.531

2.  A PTEN translational isoform has PTEN-like activity.

Authors:  Xie Zhang; Bowei Yin; Fangfang Zhu; Guochang Huang; Hong Li
Journal:  Chin J Cancer Res       Date:  2015-10       Impact factor: 5.087

3.  Pten deletion in Dmp1-expressing cells does not rescue the osteopenic effects of Wnt/β-catenin suppression.

Authors:  Kyung-Eun Lim; April M Hoggatt; Whitney A Bullock; Daniel J Horan; Hiroki Yokota; Frederick M Pavalko; Alexander G Robling
Journal:  J Cell Physiol       Date:  2020-06-11       Impact factor: 6.384

4.  Therapeutic targeting of cancers with loss of PTEN function.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

5.  Tumour suppressors: PTEN surprise.

Authors:  Sarah Seton-Rogers
Journal:  Nat Rev Cancer       Date:  2013-07-04       Impact factor: 60.716

6.  Pills of PTEN? In and out for tumor suppression.

Authors:  Antonella Papa; Ming Chen; Pier Paolo Pandolfi
Journal:  Cell Res       Date:  2013-08-06       Impact factor: 25.617

7.  PTEN, here, there, everywhere.

Authors:  C Bassi; V Stambolic
Journal:  Cell Death Differ       Date:  2013-12       Impact factor: 15.828

Review 8.  Reactive nitrogen species and hydrogen sulfide as regulators of protein tyrosine phosphatase activity.

Authors:  Petr Heneberg
Journal:  Antioxid Redox Signal       Date:  2014-03-11       Impact factor: 8.401

Review 9.  Balancing Proliferation and Connectivity in PTEN-associated Autism Spectrum Disorder.

Authors:  Amanda K Tilot; Thomas W Frazier; Charis Eng
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

Review 10.  Regulation and modulation of PTEN activity.

Authors:  Elahe Naderali; Amir Afshin Khaki; Jafar Soleymani Rad; Alireza Ali-Hemmati; Mohammad Rahmati; Hojjatollah Nozad Charoudeh
Journal:  Mol Biol Rep       Date:  2018-08-25       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.